The Priority Review

Tag

Interlude Biopharma

1 story

Stories

  1. Clinical trials

    Interlude Biopharma registers Phase 3 trial of larazotide acetate in celiac disease

    The study plans to enroll 414 participants and is expected to start in February 2027, with primary completion projected for August 2028. It is a randomized, double-blinded, placebo-controlled trial testing two doses of larazotide acetate to learn if it can help prevent signs and symptoms of celiac disease in well-controlled patients aged 12 and up.